Human Oncology & Pathogenesis Program
The Maurizio Scaltriti Lab
My group is focused on understanding why some tumors respond better than others to the inhibition of a given target and how tumor cells cope with pharmacological pressure over time.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, Baselga J. Science. 2019 Nov 8;366(6466):714-723.
Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, Guzman S, Tuch BB, Ebata K, de Stanchina E, Nagy RJ, Lanman RB, Houck-Loomis B, Patel JA, Berger MF, Ladanyi M, Hyman DM, Drilon A, Scaltriti M. Nat Med. 2019, Sep;25(9):1422-1427
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. J Clin Oncol. 2018 Aug 20;36(24):2532-2537
Tumor specific PI3K inhibition via nanoparticle targeted delivery in head and neck squamous cell carcinoma. Aviram Mizrachi, Yosi Shamay, Janki Shah, Samuel I. Brook, Joanne Soong, Vinagolu K. Rajasekhar, John L. Humm, John H. Healey, Simon N. Powell, José Baselga, Daniel A. Heller*, Adriana Haimovitz-Friedman* and Maurizio Scaltriti*. *Corresponding Authors. Nat Commun, 2017 Feb 13;8:14292
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. Cancer Cell. 2016 Aug 8;30(2):229-42. doi: 10.1016/j.ccell.2016.06.004. Epub 2016 Jul 21.
Maurizio Scaltriti, PhD
- Maurizio Scaltriti studies molecular vulnerabilities and mechanisms of tumor adaptation to targeted therapy.
- [email protected]
- Email Address
Lab News & Events
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Maurizio Scaltriti discloses the following relationships and financial interests:
General Dynamic, Information Technology
Provision of Services
Medendi Medical Travel
Ownership / Equity Interests
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.